title: [New breakthroughs in Oncodermatology].
abstract: During this year 2010, Oncodermatology was again the object of numerous publications. From the analysis of articles published between October 2009 and October 2010, choices had to be made. Overall, update on skin cancer has been dominated this year by breakthroughs on melanoma, which blows a wind of hope raised by the results of several clinical trials. Among those, it could be shown for the first time that a molecule was able to increase the overall survival of our patients (Ipilimumab). Spectacular results have also been obtained using anti-RAF. It seems that 2010 could be considered as a turning point in the therapeutic management of this cancer. In the field of lymphomas, several systemic treatments showed encouraging results in phase II and phase III trials.
authors.affiliation: Clinique de Dermatologie, CHRU Lille, rue Michel Polonovski, 59037 Lille, France. laurent.mortier@chru-lille.fr
authors.forename: L
authors.initials: L
authors.lastname: Mortier
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003880:Dermatology / Q000639:trends*; D005500:Follow-Up Studies; D006801:Humans; D000074324:Ipilimumab; D008223:Lymphoma / Q000188:drug therapy; D008495:Medical Oncology / Q000639:trends*; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab; D019908:Proto-Oncogene Proteins c-raf